Podcasts about Pfizer

The high cost associated with cancer diagnosis, treatment, and survivorship makes the burden of financial toxicity an unavoidable reality for many patients—and makes financial navigators central to the delivery of high-quality cancer care. In this vodcast episode, CANCER BUZZ speaks with Heather Simpson, BCPA, patient financial navigator lead, who shares her experience using the ACCC Financial Advocacy Network's financial advocacy services guidelines assessment tool to pinpoint financial navigation challenges within her cancer program. Heather Simpson, BCPA Patient Financial Navigator Lead              Allina Health Cancer Institute   River Falls, WI “When [ACCC] came out with a gap assessment tool in 2024...it allowed us to see where we had hit the mark with our program and where we had some gaps we could take care of to really be in line with the [Financial Advocacy Network's] guidelines.” Resources: Financial Advocacy Guidelines Financial Advocacy Services Assessment Tool Financial Advocacy Services Guidelines Assessment Tool User Guide In the Field: Practical Financial Advocacy Strategies for Supporting Cancer Patients Oncology Reimbursement Meetings This podcast is made possible by funding and support provided by Genentech, Eisai, Pfizer, and Regeneron and in partnership with AONN+, NPAF, Triage Cancer, and CancerCare.  

Interview with Dr. Kirk Moore, Utah Doctor/Surgeon, Patients Rights Advocate,  FreedomSurgicalUtah.comFollow Debbie Georgatos, America Can We Talk Show HostWebsite: http://americacanwetalk.orgTwitter: @DebbieCanWeTalkTruth: https://truthsocial.com/@AmericaCanWeTalkInstagram: https://www.instagram.com/debbiecanwetalkFacebook: https://www.facebook.com/AmericaCanWeTalkRumble: https://rumble.com/user/AmericaCanWeTalkOBBM: https://www.obbmnetwork.tv/series/america-can-we-talk-207873America Can We Talk is a show with a mission — to speak up for the extraordinary and unique greatness of America. I talk about the top issues of the day facing America, often with insightful guests, always from the perspective of furthering that mission, and with the goal to inspire listeners to celebrate and embrace the liberty on which America was founded. #BecauseAmericaMatters #AmericaCanWeTalk, #DebbieGeorgatos, #DrKirkMoore, #Truth, #Freedom, #MedicalFreedom, #TuckerCarlson, #America, #America250, #Health, #Courage, #Pfizer, #Moderna, #PatientsRights, #Covid, #Covid19, #DonaldTrump, #DrMalone, #Texas, #Utah, #Doctors, #Midterms

KIMCHI ONE – heal your body from the inside out. Visit: https://mybrightcore.com/andweknow and get 25% off with code: AWK Or call (888) 317-9941) for up to 50% off! INTERVIEW: https://shorturl.at/sAe0b ——— Visit CBD: (http://cbdistillery.com/) and use code LT for 25% off! ——— Protect your investments with And We Know http://andweknow.com/gold Or call 720-605-3900, Tell them “LT” sent you. ------ AT sea with LT. 2026. Caribbean: https://www.inspirationtravel.com/event/lt-caribbean-cruise-2026 ————————— *Our AWK Website: https://www.andweknow.com/ ➜ AWK Shirts and gifts: https://shop.andweknow.com/ ------- Robert F Kennedy: "It's a trick". https://x.com/Humanspective/status/1962442350644568123 Elon Musk calls for Muslim Imam Abdullah Faaruuq (Boston, Massachusetts) to be deported after he declares white Americans should go back to Europe. https://x.com/RedWave_Press/status/1962670199112450450 Democrats on CNN are now passionately defending keeping children separated from their properly deported parents. https://x.com/Bubblebathgirl/status/1962630535873769741 Democrats in Michigan have been creating thousands of fake jobs and then laundering that money back to themselves https://x.com/WallStreetApes/status/1962499847594156257 RFK JR: “If you look at the studies that were done of the Pfizer vaccine … the people who got the vaccine had a 23% higher death rate from all causes” https://x.com/TheChiefNerd/status/1962600003534246209 ——  *DONATIONS SITE: https://bit.ly/2Lgdrh5 *Mail your gift to: And We Know 30650 Rancho California Rd STE D406-123 (or D406-126) Temecula, CA 92591 ➜ AWK Shirts and gifts: https://shop.andweknow.com/ ➜ Audio Bible https://www.biblegateway.com/audio/mclean/kjv/1John.3.16 Connect with us in the following ways: + DISCORD Fellows: https://discord.gg/kMt8R2FC4z

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

Waardeer je onze video's? Steun dan Café Weltschmerz, het podium voor het vrije woord: https://www.cafeweltschmerz.nl/doneren/Doodenge uitspraken: Timmermans noemt Oekraïense soldaten ''onze soldaten''Week 36 zet de frontlijn in beeld.Troepen naar Oekraïne?Trump blaast Warp Speed nieuw leven in.RFK onder vuur, blijft staan.AFDers vallen met bosjes om.Grok blijkt hardcoded voor narratieven.NCTV antwoordt, maar zwijgt over de kern.Gemeente Zundert schrijft een boek over Fort Oranje.Rapport van Pfizer erkent DNA in de prikken.---Deze video is geproduceerd door Café Weltschmerz. Café Weltschmerz gelooft in de kracht van het gesprek en zendt interviews uit over actuele maatschappelijke thema's. Wij bieden een hoogwaardig alternatief voor de mainstream media. Café Weltschmerz is onafhankelijk en niet verbonden aan politieke, religieuze of commerciële partijen.Wil je meer video's bekijken en op de hoogte blijven via onze nieuwsbrief? Ga dan naar: https://www.cafeweltschmerz.nl/videos/Wil je op de hoogte worden gebracht van onze nieuwe video's? Klik dan op deze link: https://bit.ly/3XweTO0

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/PXM865. CME/MOC/AAPA credit will be available until August 26, 2026.From Migraine Recognition to Relief: Improving Outcomes With Patient-Centered CGRP Antagonist Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

Professor Dame Carol Robinson is a scientist who was the first female professor of Chemistry at both Cambridge and Oxford Universities. She has been awarded scientific prizes from all over the world for her pioneering work studying complex macromolecules using an instrument called the mass spectrometer.Carol was drawn to science as a child growing up in Folkstone where she started collecting flowers and shells before moving on to breeding mice because she was fascinated by their genetic makeup. She grew to love chemistry in particular and pored over the periodic table in her bedroom.She left school at 16 and joined Pfizer, the pharmaceutical and biomedical company, as a laboratory technician. At Pfizer she began working with the mass spectrometer which measures the mass of all the atoms in a particular sample. She studied for an ONC and HNC in Chemistry in the evenings and at weekends and later gained a PHD in Chemistry from Cambridge University.She was appointed DBE in 2013 for services to science and industry. In 2021 she founded the Kavli Institute for NanoScience Discovery, an interdisciplinary science institute dedicated to studying structures and materials at an ultra-small scale.Carol has three children from her first marriage and lives in Oxfordshire with her second husband David. DISC ONE: Girl on Fire - Alicia Keys DISC TWO: She's Leaving Home - The Beatles DISC THREE: Prokofiev: Romeo and Juliet Suite No. 2, Op. 64b: I. Montagues and Capulets - Dance of the Knights. Performed by London Symphony Orchestra, conducted by Claudio Abbado DISC FOUR: Sonnet - The Verve DISC FIVE: Wild Horses - The Rolling Stones DISC SIX: Golden Brown - The Stranglers DISC SEVEN: Stairway to Heaven - Led Zeppelin DISC EIGHT: The Scientist - Coldplay BOOK CHOICE: The Herbal Apothecary: 100 Medicinal Herbs and How to Use Them by JJ Pursell LUXURY ITEM: A portable mass spectrometer CASTAWAY'S FAVOURITE: Stairway to Heaven - Led ZeppelinPresenter Lauren Laverne Producer Paula McGinley

For the first time, Donald Trump publicly questioned Operation Warp Speed and mRNA shots during the pandemic. “Many people think they are a miracle that saved Millions of lives. Others disagree!” writes the President. “I hope OPERATION WARP SPEED was as “BRILLIANT” as many say it was. If not, we all want to know about it, and why???” “To date I have seen no evidence that any manufacturer of these magic potions consistently produces what they claim they produce,” says Sasha Latypova. Sasha Latypova is a retired pharma R&D executive with 25 years of experience. She managed contract research organizations, working with over 60 pharma companies, including Pfizer and Novartis. She specialized in cardiovascular safety and interacted with the FDA. Follow at https://x.com/sasha_latypova⠀Chloe Carmichael, Ph.D., is a clinical psychologist and USA Today bestselling author. She serves on the Women's Health Magazine Advisory Board and is a fellow at the Independent Women's Forum. She authored “Can I Say That?” and “Nervous Energy.” Learn more at https://drchloe.com 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/sponsors⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

NEW: Send us Your Comments!This Week's Topics:RFK Jr. Takes on Big Pharma Senators 3:30No More Blocking of Medical Records 12:00Trump Demands Answers from Pfizer 15:30$10 Nasal Spray more Effective than Vax 18:30Florida Ends ALL Vax Mandates 21:30VIDEO: Trump winning Big on Crime 24:30New Evidence of Auto-Pen Misuse 31:30Trump Deports 250,000 Venezuelans 35:00HUD Pushing Illegals Out 36:00Finally Home Sales Start to Rise 39:00Jobs Report will Trigger Interest Rate Cut 41:00Dems think our Right Come from Them! 43:00Trump Approval at 55% 47:30China, Russia & India Meet for Parade 56:00VIDEO: Trump Announces Dept. of War 1:01:00France's Government will Collapse 1:03:00AfD Candidates in Germany Dying 1:06:00Feds Stop Huge Drug Shippment 1:07:30US Blows Up Drug Cratel Boat 1:11:00Alligator Alcatrazto stay open! 1:14:00Stop Transgenders from Owning Guns? 1:15:30Thune Holding Up Trump Appointments 1:17:30No more Paper Checks from IRS or SSA 1:21:30FTC Takes Action Against Porn Hub 1:23:00Schwarzenegger Leads CA Fight 1:25:00Google Skates in Anti-Trust Case 1:26:30Epstein files are a Political Hit Job 1:30:30Tom Z's Talks to Cracker Barrel 1:41:00Support the showView our Podcast and our other videos and news stories at:www.WethePeopleConvention.orgSend Comments and Suggestions to:info@WethePeopleConvention.org

In this episode, Michael and Josh continue to unpick the thorny question of germ-cell tumours, focusing this week on more advanced and relapsed disease. Germ cell tumours have an excellent prognosis, but unfortunately there are cases where more intense therapy is required. Listen on to find out about what to do when first line therapy is not enough!Studies discussed in this episodeBEP - Williams et al (1987)TIP - Gleeson et al (20224)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Jimmy and Children's Health Defense's Mary Holland discuss Donald Trump's recent shift in tone on Operation Warp Speed, highlighting his ultimatum to Pfizer to release full data on COVID-19 vaccines. They frame this as Trump aligning more closely with RFK Jr., who has long criticized vaccine safety and pandemic policies.  The two accuse Pfizer of fraud, cover-ups, and knowingly downplaying vaccine injuries, while suggesting legal consequences under the PREP Act for willful misconduct. They argue that Trump was misled by Anthony Fauci, Francis Collins, and Big Pharma interests, and that a broader “COVID reckoning” is coming as lies and conflicts of interest are exposed. Plus segments on the pushback RFK received after rooting out Big Pharma shills from the CDC and Trump's boasting about killing 11 suspected “drug runners” from Venezuela in the Caribbean Sea. Also featuring Stef Zamorano!

Episode Highlight: In this episode of the Embracing “Only” podcast, we welcome back bestselling author and corporate change-maker Mita Mallick. With her signature candor, Mita shares wisdom from her upcoming book The Devil Emails at Midnight: What Good Leaders Can Learn from Bad Bosses, which explores 13 “devil boss” archetypes, drawing on personal stories and real-life failures turned into lessons in leadership. Mita is a Wall Street Journal and USA Today bestselling author on a mission to fix what's broken in our workplaces. With a background spanning global brands like Unilever, Pfizer, and Johnson & Johnson, Mita brings deep insight into marketing, HR, and organizational transformation. Key Discussion Points:02:58 Why Good People Become Bad Bosses: Stress in the market, pressure from above, or personal issues at home can cause leaders to act out in harmful ways.06:29 Beloved but Incompetent Leaders: Mediocre men keep getting promoted based on potential, while overqualified women of color are passed over.12:30 Diversity Under Attack: As corporate DEI commitments backslide, Mita challenges companies to stand firm and urges employees to "vote with their wallets”.16:48 Internal vs. External Consistency: If your external brand doesn't match your internal culture, expect to be called out.21:39 Building a Personal Safety Net: Loyalty is dead. Women of color must protect themselves in workplaces that don't always protect them.29:08 Burnout & Overfunctioning: Women of color are told to "work twice as hard" to get half as far. This is exploitation masked as opportunity.33:24 The Midnight Email Culture: What does it say about a company when leaders only respond between 10 PM and 1 AM?In Summary: Mita Mallick encourages us to reimagine leadership in modern workplaces. She challenges leaders to prioritize coaching and development, create inclusive environments, and maintain genuine commitments to diversity and ethical practices.Resources from this episode:Find Mita's books here: https://www.mitamallick.com/bookFollow Mita on Linkedin or check out her website.Check out our first episode with Mita here: https://embracingonly.com/episodes/debunking-corporate-myths-to-transform-your-workplace If you happen to be a woman of color and you are looking for a community of like minded women, join Olivia here: https://www.mysistersshoulders.com/.Ready to make a change?→ If you are struggling to navigate your corporate career but are ambitious and have goals you want to accomplish quickly, Olivia is the coach for you. She can help you reach your goals. Reach out to her on LinkedIn or visit oliviacream.com.→ If you are ready to transition out of Corporate and want to start building a profitable portfolio career as a business owner, board member or more, but you're unsure of the next steps, Archita can guide you through a successful transition to entrepreneurship. Reach out to her on Ready to make a change?→ Struggling with your corporate career but have big goals? Reach out to Olivia on LinkedIn or visit oliviacream.com.→ Ready to leave corporate or start a side venture? Archita can guide your next steps.Reach out to her on LinkedIn or visit architafritz.com.

Get ready to explore the future of music and media with Adams Fan, Chief Creative Officer of F5 Shanghai, China's most awarded independent agency at Cannes Lions. Adams flips the interview with Dana Leong, sharing visionary insights drawn from his trailblazing career leading breakthrough creative campaigns for global giants like Pfizer, Lenovo, Saudi Tourism, and more.Known for blending technology, storytelling and cultural trends, Adams reveals where the music and media industries are headed, and how creators can stay ahead in a rapidly shifting landscape. Dana also shares why he values Adams as a creative kindred spirit and relentless hustler.Tune in as these two visionaries break down innovation, creativity, and the evolving business of entertainment.--Welcome back to #UpgradeMePod. It's a podcast about the never ending self improvement journey, ideas and life hacks to help you level up and the people who make it happen! Hosted by Dana Leong, a 2x Grammy Winning Musician, a US Musical Ambassador and a World Economic Forum Young Global Leader. Join our communities online at:https://www.Instagram.com/UpgradeMePodhttps://www.TikTok.com/@UpgradeMePodhttps://www.Facebook.com/UpgradeMePodhttps://www.youtube.com/channel/UCz78FK-d4PsebeDbKaArigwhttps://www.soundcloud.com/UpgradeMePodhttps://x.com/PodUpgradehttps://www.linkedin.com/in/DanaLeongSubscribe to Upgrade Me: https://bit.ly/upgradeytsub#UpgradeMe is sponsored by TEKTONIKmusic.org (Harmony Heals)#danaleong #grammy #motivation #billionaire #podcast #inspiration #selfimprovement #mentalhealth #Motivation #LifeHacks #Advertising #CEO #AdamsFan #F5

Buckle up, patriots—@intheMatrixxx and @shadygrooove blaze through Season 7, Episode 168, “RFK Jr. Testifies at Senate Hearing Amid CDC Chaos; Putin Talks IMMORTALITY,” airing live on September 4, 2025, at 12:05 PM Eastern! These truth-warrior hosts dissect HHS Secretary Robert F. Kennedy Jr.'s fiery Senate testimony, grilling the establishment on CDC upheaval—from firing Director Susan Monarez and top resignations to overhauling vaccine policies amid accusations of hidden myocarditis signals, manipulated safety data, and links to autism risks in studies like the Atlanta MMR research. Jeff and Shannon expose pharmaceutical giants' grip on politicians through massive donations to figures like Maria Cantwell and Maggie Hassan, prioritizing profits over public health, while championing transparency in drug approvals, unvaccinated vs. vaccinated health comparisons, and cracking down on federal healthcare fraud via CMS initiatives and rural health reforms. They slam the Biden era's COVID vaccine push as a test run for control, with celebs and officials like Obama and Fauci downplaying dangers, and question the media's Pfizer-sponsored spin. Then, they turn to Vladimir Putin's hot-mic musings with Xi Jinping on biotechnology, organ transplants, and achieving immortality—unearthing potential globalist plots in anti-aging pursuits. With razor-sharp wit, live intel drops, and real-time takedowns, the MG Show urges accountability in the medical system and a rejection of entrenched corruption. The truth is learned, never told—wield the Constitution as your weapon and tune in at noon-0-five Eastern LIVE to stand with Trump! Trump, RFK Jr., CDC chaos, vaccines, vaccine safety, pharma influence, myocarditis, autism, Putin, immortality, MG Show, @intheMatrixxx, @shadygrooove, America First, Senate hearing, healthcare reform, corruption, COVID data mgshow_s7e168_rfk_testifies_cdc_chaos_putin_immortality Where to Watch & Listen Live on https://rumble.com/mgshow https://mgshow.link/redstate X: https://x.com/inthematrixxx Backup: https://kick.com/mgshow PODCASTS: Available on PodBean, Apple, Pandora, and Amazon Music. Search for "MG Show" to listen. Engage with Us Join the conversation on https://t.me/mgshowchannel and participate in live voice chats at https://t.me/MGShow. Social & Support Follow us on X: @intheMatrixxx https://x.com/inthematrixxx @ShadyGrooove https://x.com/shadygrooove Support the show: Fundraiser: https://givesendgo.com/helpmgshow Donate: https://mg.show/support Merch: https://merch.mg.show MyPillow Special: Use code MGSHOW at https://mypillow.com/mgshow for savings! Wanna send crypto? Bitcoin: bc1qtl2mftxzv8cxnzenmpav6t72a95yudtkq9dsuf Ethereum: 0xA11f0d2A68193cC57FAF9787F6Db1d3c98cf0b4D ADA: addr1q9z3urhje7jp2g85m3d4avfegrxapdhp726qpcf7czekeuayrlwx4lrzcfxzvupnlqqjjfl0rw08z0fmgzdk7z4zzgnqujqzsf XLM: GAWJ55N3QFYPFA2IC6HBEQ3OTGJGDG6OMY6RHP4ZIDFJLQPEUS5RAMO7 LTC: ltc1qapwe55ljayyav8hgg2f9dx2y0dxy73u0tya0pu All Links Find everything on https://linktr.ee/mgshow

You are in for a dose of inspiration in this episode of Raise the Line as we introduce you to a rare disease patient who was a leading force in establishing the diagnosis for her own condition, who played a key role in launching the first phase three clinical trials for it, and who is now coordinating research into the disease and related disorders at one of the nation's top hospitals. Rebecca Salky, RN, was first afflicted at the age of four with MOGAD, an autoimmune disorder of the central nervous system that can cause paralysis, vision loss and seizures. In this fascinating conversation with host Lindsey Smith, Rebecca describes her long and challenging journey with MOGAD, her work at the Neuroimmunology Clinic and Research Lab at Massachusetts General Hospital, and the importance of finding a MOGAD community in her early twenties. “There's a sense of power and security when you have others on your side. You're not alone in this journey of the rare disease,” she explains. Be sure to stay tuned to learn about Rebecca's work in patient advocacy, her experience as a nurse, and the three things she thinks are missing in the care of rare disease patients as our Year of the Zebra series continues.Mentioned in this episode:The MOG ProjectNeuroimmunology Clinic & Research Lab at Mass General If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Professor of electrical engineer and computer science Ben Recht joins us to defend Bayesianism, AI doom, and assure us that the statisticians have everything under control. Just kidding. Recht might be even more suspicious of these things than we are. What has statistics ever done for us, really? When was the last time YOU ran a clinical trial after all, huh? HUH? After Ben Chugg defends his life decision to do a PhD in statistics, we talk AI, cults, philosophy, Paul Meehl, and discuss Ben Recht's forthcoming book, The Irrational Decision (https://press.princeton.edu/books/hardcover/9780691272443/the-irrational-decision). Check out Ben's blog (https://www.argmin.net/), website (https://people.eecs.berkeley.edu/~brecht/), and his story about machine learning (https://mlstory.org/). We discuss Ben Recht's theory of blogging Why is Berkeley the epicenter of AI doom? Where the word "robot" came from Is Bayesian reasoning responsible for AI doom? Paul Meehl and his contributions to science Ben Recht's bureaucratic theory of statistics What on earth is null hypothesis testing? What is the point of statistics? "Sweet spots" and "small worlds" Does science proceed by Popperian means? Can Popper get around the Duhem-Quine problem? Errata The z-score for the Pfizer trial was 20, not 12! References Argmin (https://www.argmin.net/), Ben Recht's blog David Freedman, UC Berkeley (https://statistics.berkeley.edu/about/biographies/david-freedman) Paul Meehl's online course (https://www.youtube.com/@michaelmcgovern8633/featured) Theoretical Risks and Tabular Asterisks: Sir Karl, Sir Ronald, and the Slow Progress of Soft Psychology (https://errorstatistics.com/wp-content/uploads/2015/04/meehl-1978.pdf), Paul Meehl's 1978 paper. Clinical versus statistical prediction: A theoretical analysis and a review of the evidence (https://psycnet.apa.org/record/2006-21565-000), by Meehl On the near impossibility of estimating the returns to advertising (https://ftp.zew.de/pub/zew-docs/veranstaltungen/ICT2013/Papers/ICT2013_Rao.pdf) A Bureaucratic Theory of Statistics (https://arxiv.org/pdf/2501.03457) by Recht The new riddle of induction (https://fitelson.org/confirmation/goodman_1955.pdf) by Goodman Announcing the Irrational Decision (https://www.argmin.net/p/announcing-the-irrational-decision) Patterns, Predictions, and Actions (https://mlstory.org/), textbook by Ben Recht and Moritz Hardt Socials Follow us on Twitter at @BeenWrekt, @IncrementsPod, @BennyChugg, @VadenMasrani Come join our discord server! DM us on twitter or send us an email to get a supersecret link Become a patreon subscriber here (https://www.patreon.com/Increments). Or give us one-time cash donations to help cover our lack of cash donations here (https://ko-fi.com/increments). Click dem like buttons on youtube (https://www.youtube.com/channel/UC_4wZzQyoW4s4ZuE4FY9DQQ) What's Berkeley's next cult? Send your guess over to incrementspodcast@gmail.com Special Guest: Ben Recht.

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

Are you looking to save time, make money, and start winning with less risk? Then head to https://www.ovtlyr.com.If you've ever wondered whether you can truly live off dividends, this video breaks it all down in plain English. We're taking a deep dive into dividend investing strategies, looking at what works, what doesn't, and why chasing high yields can be riskier than it looks. You'll discover how some investors with less than $500,000 are already living off dividends, why Johnson & Johnson's 2.9% yield is both attractive and limited, and how a stock's price growth can often dwarf its dividend payouts.The video explores the real math behind dividend yields, capital appreciation, and how compounding growth changes the game. You'll see examples like JNJ up 24% year to date, covered call ETFs generating steady income, and REITs offering additional streams of cash flow. But there's also a warning—stocks like UPS and Pfizer may boast 6% to 7% dividends, but if the share price drops 30%, that income doesn't look so appealing. The truth is, focusing only on yield often means missing the bigger picture.We also compare different approaches: blue chip dividend stocks, Treasury ETFs with near-zero risk, covered call ETFs like QYLD and JEPI, and even ultra-high-yield funds like YieldMax. Each comes with trade-offs. Some offer consistency but limited growth, others carry massive risk despite eye-popping yields. By the end, you'll understand how to balance income with growth, and why protecting your principal is just as important as generating cash flow.A big focus here is taxes and classifications. Dividends aren't all equal—some are qualified and taxed at lower capital gains rates, while others are ordinary income taxed at your highest bracket. Covered call ETFs often include return of capital, which can defer taxes but also lower your cost basis. These details matter if you're planning to retire early or live off passive income before traditional retirement age.This isn't just theory. The strategies covered include real-world examples of dividend stocks, REITs, ETFs, and funds being used right now. You'll learn why “all stocks are bad but sometimes they act right” and how to recognize those moments with tools like the OVTLYR trend template. More importantly, you'll see why sitting in cash at 4% APY might sometimes beat chasing risky yields.Whether you're aiming for financial freedom, retirement income, or just smarter portfolio management, this video shows how dividend strategies really play out in practice. The goal isn't just collecting drips of cash—it's capturing the flood of opportunity when growth and income align.➡️ Learn why dividend investing isn't a one-size-fits-all approach➡️ See how to spot traps in “too good to be true” high yields➡️ Compare low-risk vs. high-yield income strategies➡️ Understand the tax implications of dividends and ROC➡️ Use OVTLYR's behavioral analytics to know when to hold and when to move to cashGain instant access to the AI-powered tools and behavioral insights top traders use to spot big moves before the crowd. Start trading smarter today

00:00:44 – Trump Blocked as “Police Chief” A judge rules Trump cannot act as a national police chief after his attempted troop deployments in U.S. cities, raising alarms about his dictatorial impulses. 00:09:47 – Venezuela Drug Strike Trump brags about a U.S. military strike on a boat off Venezuela, alleging drug cartel ties. Critics warn this mirrors past failed wars. 00:35:04 – Martial Law by “One City at a Time” Commentary warns Trump and GOP leaders are normalizing martial law city by city under the guise of fighting crime, mirroring pandemic lockdown logic. 00:52:25 – Trans Migrant Murders Father An illegal Indian transgender individual murders a Massachusetts father after being confronted for graffiti. Media and police suppress the story despite his prior violent record. 00:54:21 – UK Comedian Arrested for Tweets British comedian Graham Linehan is arrested upon arrival in London for anti-trans tweets. Police deploy armed officers, strip-search him, and gag his speech—praised by JK Rowling as proof of UK totalitarianism. 01:13:57 – AI Seances: Talking to the Dead Discussion of new “digital afterlife” tech that lets people chat with AI simulations of deceased relatives. Critics call it ancestor worship and a dangerous psychological manipulation. 01:22:47 – Mental Health Surveillance in Schools Illinois and other states push universal mental health screenings, funneling kids into psychiatric labels and drugs. Commentary ties it to Trump's lockdown damage and Melania's push for total child monitoring. 02:15:12 – mRNA Declared Bioweapon Florida's World Council for Health declares mRNA injections weapons of mass destruction. A proposed Bioweapons Prohibition Act argues these shots are already illegal under state laws. 02:21:11 – Trump's Vaccine Cover-Up Trump now demands Pfizer “prove” vaccine effectiveness—five years late. Critics argue he's running a cover-up inquiry like JFK or Climategate commissions, designed to whitewash his own Operation Warp Speed. 02:29:38 – Generational Slaughter in Care Homes Scottish and English inquiries reveal COVID policy killed thousands in care homes through lockdowns, ventilators, and midazolam. Critics stress this was state-orchestrated culling, not viral inevitability. 02:36:26 – Turbo Cancers in Italy Peer-reviewed Italian study of 300,000 people shows vaccinated individuals face 35% higher hospitalization for cancer, with sharp increases in breast, bladder, and colorectal cancers. 02:39:38 – Woody Allen Praises Trump Woody Allen lauds Trump while railing against cancel culture. Critics highlight his Epstein ties and pedophilia allegations, framing his defense of Trump as another elite protecting elites. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

00:00:44 – Trump Blocked as “Police Chief” A judge rules Trump cannot act as a national police chief after his attempted troop deployments in U.S. cities, raising alarms about his dictatorial impulses. 00:09:47 – Venezuela Drug Strike Trump brags about a U.S. military strike on a boat off Venezuela, alleging drug cartel ties. Critics warn this mirrors past failed wars. 00:35:04 – Martial Law by “One City at a Time” Commentary warns Trump and GOP leaders are normalizing martial law city by city under the guise of fighting crime, mirroring pandemic lockdown logic. 00:52:25 – Trans Migrant Murders Father An illegal Indian transgender individual murders a Massachusetts father after being confronted for graffiti. Media and police suppress the story despite his prior violent record. 00:54:21 – UK Comedian Arrested for Tweets British comedian Graham Linehan is arrested upon arrival in London for anti-trans tweets. Police deploy armed officers, strip-search him, and gag his speech—praised by JK Rowling as proof of UK totalitarianism. 01:13:57 – AI Seances: Talking to the Dead Discussion of new “digital afterlife” tech that lets people chat with AI simulations of deceased relatives. Critics call it ancestor worship and a dangerous psychological manipulation. 01:22:47 – Mental Health Surveillance in Schools Illinois and other states push universal mental health screenings, funneling kids into psychiatric labels and drugs. Commentary ties it to Trump's lockdown damage and Melania's push for total child monitoring. 02:15:12 – mRNA Declared Bioweapon Florida's World Council for Health declares mRNA injections weapons of mass destruction. A proposed Bioweapons Prohibition Act argues these shots are already illegal under state laws. 02:21:11 – Trump's Vaccine Cover-Up Trump now demands Pfizer “prove” vaccine effectiveness—five years late. Critics argue he's running a cover-up inquiry like JFK or Climategate commissions, designed to whitewash his own Operation Warp Speed. 02:29:38 – Generational Slaughter in Care Homes Scottish and English inquiries reveal COVID policy killed thousands in care homes through lockdowns, ventilators, and midazolam. Critics stress this was state-orchestrated culling, not viral inevitability. 02:36:26 – Turbo Cancers in Italy Peer-reviewed Italian study of 300,000 people shows vaccinated individuals face 35% higher hospitalization for cancer, with sharp increases in breast, bladder, and colorectal cancers. 02:39:38 – Woody Allen Praises Trump Woody Allen lauds Trump while railing against cancel culture. Critics highlight his Epstein ties and pedophilia allegations, framing his defense of Trump as another elite protecting elites. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Global yields spiking overnight as investors work through fresh JOLTS data and tariff developments: Carl Quintanilla and Sara Eisen broke down the latest moves alongside fresh Fed commentary and economic data top of the hour. Counselor to the Treasury Secretary, Joe Lavorgna joined the team to discuss it all – arguing the economy remains strong here – in addition to Jefferies Chief Market Strategist, and potential Fed contender David Zervos later on. Also in focus: what to do with Google shares after their big antitrust trial win… Why Evercore calls this a “clearing event” for the stock – and says you should buy the stock here.  Plus: hear Pfizer's official response to recent claims around their COVID vaccines… And a recap of August auto sales numbers – along with more on what could come next. 

This segment delves into the growing skepticism surrounding COVID-19 vaccines and the alleged conspiracy to mislead the American public. The host highlights Robert F. Kennedy Jr.'s move to revoke the emergency use authorization for the vaccines, arguing it's a necessary step to re-establish proper scientific protocols, including double-blind trials. The discussion also focuses on a "massive reversal" by President Donald Trump, who is now demanding that Pfizer release hidden data related to Operation Warp Speed. The speaker suggests that Trump was misled by pharmaceutical companies and figures like Dr. Anthony Fauci, who, according to the host, deliberately lied to the public to benefit big pharma. The segment claims that the vaccines were not only ineffective but also dangerous, and that the rising death toll reported to VAERS is evidence of a massive cover-up, a scandal of the century.

Alex Goryachev is a Forbes-recognized innovation expert and Wall Street Journal Bestselling author. In this episode, he shares his expertise on harnessing the power of AI to drive transformative change. With hands-on experience at top brands like Cisco, Dell, IBM, and Pfizer, Alex cuts through the hype and delivers authentic, actionable insights on overcoming AI resistance and sparking innovation.   Links: Alex's Website: https://www.alexgoryachev.com/

US-Präsident Donald Trump fordert die großen Pharmaunternehmen auf, der Öffentlichkeit Beweise für die Wirksamkeit ihrer Corona-Impfstoffe vorzulegen. Angesichts von Turbulenzen in der Seuchenschutzbehörde CDC und wachsendem Zweifel in Teilen der Gesellschaft verlangt Trump Transparenz – und entfacht eine neue Debatte um die Pandemie und Impfungen.

Herzlich willkommen zu Ihrem morgendlichen Newsletter! Nach wiederholten Angriffen der Ukraine auf die Druschba-Pipeline verschärfen sich die Spannungen zwischen Budapest und Kiew. Details dazu erfahren Sie in unserem ersten Beitrag. Donald Trump fordert nun von Pfizer & Co. einen Erfolgsnachweis für ihre Impfstoffe. Er entfacht damit eine spannende Debatte, die wir in unserem zweiten Beitrag genauer untersuchen. Der GPS-Ausfall während von der Leyens Flug in Bulgarien löst ein geteiltes Echo aus. Flightradar24-Daten sagen, dass es gar keinen Ausfall gegeben habe. Näheres erfahren Sie in unserem letzten Artikel.

Victoria Lozano is Chief Marketing Officer at Crayola LLC where she oversees all aspects of marketing and consumer engagement for one of the world's most iconic and cherished brands. For over 120 years, Crayola has been synonymous with nurturing children's creativity. Today, it is recognized as one of the most culturally resonant, authentic, and trusted brands globally. In her role, Victoria leads Crayola's consumer communications, partnership marketing, digital/omni-channel marketing, interactive app portfolio, and education marketing. Victoria also oversees Location Based Entertainment, which includes a portfolio of branded attraction and retail concepts that bring the Crayola brand to life in experiential ways. The flagship concept, Crayola Experience, has 4 locations across the US with several more announced both in the US and internationally. Prior to joining Crayola, Victoria was Vice President of Marketing at Cadbury North America where she led the $1.2B Gum and Mints Portfolio across the United States and Canada, including brands such as Trident, Dentyne, Stride, Bubblicious and Certs. Prior to Cadbury, Victoria held various marketing positions with Fortune 500 companies such as the Miller Brewing Company, Warner-Lambert Company and Pfizer, Inc. Victoria's academic background includes a Master of Business Administration degree from New York University with a specialization in Marketing and Finance, and a Bachelor of Science degree from New York University with focus in Marketing and Classical Studies (summa cum laude).Victoria currently serves on the board of The Children's Home of Easton located in Easton, Pennsylvania where Victoria resides with her husband and three children.

SPONSORS:   Go to https://www.blackoutcoffee.com/Graham  and use code GRAHAM at checkout for NON-WOKE Coffee!!   Go to https://www.PatriotMobile.com/GRAHAM or call 972-PATRIOT. Use promo code GRAHAM and get a FREE MONTH of service.   ✉️Subscribe to the Newsletter!! https://newsletter.grahamallen.com/

Dean Karayanis of the New York Sun fills in for Derek. Topics include the rest of the story behind the New York Times piece alleging that Black women are hardest hit by President Trump shrinking the federal workforce, John Turturro's very big performance in a small role in the Big Lebowski, Emma Watson inventing new terms for being single, and President Trump's push for transparency from Pfizer over the Covid-19 vaccine produced by Operation Warp Speed.

01:03:21 – Vaccine Industry Circling the Drain Trump suddenly calls on Pfizer and Moderna to “justify the success” of COVID shots. Analysts argue this is more about salvaging biotech profits than concern for public health. 01:13:56 – Trump the “Father of the Vaccine” Clips replay Trump bragging about Operation Warp Speed while later trying to shift blame to pharma. Commentary highlights the hypocrisy of taking credit when convenient and disowning failure when exposed. 01:24:59 – Japan's Vaccine Death Surge Japan, once highly compliant with mRNA rollout, now leads the world in excess deaths. Studies tie the crisis directly to repeated shots, sparking comparisons to black particulates found in tainted vaccine batches. 01:37:59 – Court Reopens Myocarditis Death Case A federal court reopens a lawsuit over a 24-year-old who died from vaccine-induced myocarditis, spotlighting Pentagon involvement in Operation Warp Speed and exposing legal loopholes shielding pharma and government from liability. 02:07:28 – Trump Tariffs Ruled Illegal A federal appeals court strikes down Trump's “reciprocal tariffs,” ruling that his use of emergency powers was unconstitutional and potentially forcing billions in refunds. 02:20:54 – AI as Political Weapon Trump allies deploy artificial intelligence to investigate enemies, raising warnings of Stalin's “find me the crime” updated with modern surveillance. 02:27:09 – BRICS Unites Against Trump India, Russia, and China respond to Trump's tariffs with closer cooperation, accelerating the creation of a parallel financial system. 02:29:24 – Trucker Visa Showdown A deadly crash by an Indian trucker triggers U.S. visa scrutiny, while India defends migrant drivers who undercut wages and send billions abroad. 02:49:33 – Infowars Purges Anti-Trump Voices Reports surface that Owen Shroyer was fired from Infowars for criticizing Trump, sparking charges that Alex Jones protects Trump at all costs. 03:04:23 – Alex Karp's Technocratic Republic Palantir CEO Alex Karp's new book is framed as a blueprint for a dystopian technocracy, blending despair about Silicon Valley with calls for “hard power” governance. 03:12:22 – Wright Brothers vs. State “Innovation” The Wright brothers' success is contrasted with government failure, used to argue that real innovation comes from individuals and free markets, not state subsidies. 03:19:07 – Meta-Constitution: Hidden World Government Global governance is said to already operate through NGOs, ISO standards, and digital ID systems—creating binding control without elections or constitutions. 03:41:17 – Vegas Shooting & Gun Control The Las Vegas massacre is revisited as Trump's pretext for banning bump stocks by executive order, setting precedent for future gun control. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

Trump is calling out Big Pharma, demanding they finally prove the success—or failure—of their COVID drugs. He says Pfizer and others have “extraordinary” data, yet they refuse to show it to the public, leaving the CDC and even Bobby Kennedy Jr. tangled in the mess. If Operation Warp Speed was truly “brilliant,” why is the evidence still hidden? Are these miracle shots that saved millions of lives—or a cover-up waiting to be exposed? Go to http://rumble.com/premium/brand and use code BRAND to save $10 on your annual subscription http://www.1775coffee.com/BRAND to save 15% off your order of 1775 Coffee.  

01:03:21 – Vaccine Industry Circling the Drain Trump suddenly calls on Pfizer and Moderna to “justify the success” of COVID shots. Analysts argue this is more about salvaging biotech profits than concern for public health. 01:13:56 – Trump the “Father of the Vaccine” Clips replay Trump bragging about Operation Warp Speed while later trying to shift blame to pharma. Commentary highlights the hypocrisy of taking credit when convenient and disowning failure when exposed. 01:24:59 – Japan's Vaccine Death Surge Japan, once highly compliant with mRNA rollout, now leads the world in excess deaths. Studies tie the crisis directly to repeated shots, sparking comparisons to black particulates found in tainted vaccine batches. 01:37:59 – Court Reopens Myocarditis Death Case A federal court reopens a lawsuit over a 24-year-old who died from vaccine-induced myocarditis, spotlighting Pentagon involvement in Operation Warp Speed and exposing legal loopholes shielding pharma and government from liability. 02:07:28 – Trump Tariffs Ruled Illegal A federal appeals court strikes down Trump's “reciprocal tariffs,” ruling that his use of emergency powers was unconstitutional and potentially forcing billions in refunds. 02:20:54 – AI as Political Weapon Trump allies deploy artificial intelligence to investigate enemies, raising warnings of Stalin's “find me the crime” updated with modern surveillance. 02:27:09 – BRICS Unites Against Trump India, Russia, and China respond to Trump's tariffs with closer cooperation, accelerating the creation of a parallel financial system. 02:29:24 – Trucker Visa Showdown A deadly crash by an Indian trucker triggers U.S. visa scrutiny, while India defends migrant drivers who undercut wages and send billions abroad. 02:49:33 – Infowars Purges Anti-Trump Voices Reports surface that Owen Shroyer was fired from Infowars for criticizing Trump, sparking charges that Alex Jones protects Trump at all costs. 03:04:23 – Alex Karp's Technocratic Republic Palantir CEO Alex Karp's new book is framed as a blueprint for a dystopian technocracy, blending despair about Silicon Valley with calls for “hard power” governance. 03:12:22 – Wright Brothers vs. State “Innovation” The Wright brothers' success is contrasted with government failure, used to argue that real innovation comes from individuals and free markets, not state subsidies. 03:19:07 – Meta-Constitution: Hidden World Government Global governance is said to already operate through NGOs, ISO standards, and digital ID systems—creating binding control without elections or constitutions. 03:41:17 – Vegas Shooting & Gun Control The Las Vegas massacre is revisited as Trump's pretext for banning bump stocks by executive order, setting precedent for future gun control. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

DID TRUMP JUST TURN ON BIG PHARMA? I saw the post President Trump sent out this past weekend that seemed in my view to be challenging Pfizer on what information they showed HIM when he was President and what they did NOT show anyone about the vaccines.My pal David Strom writes about this here, and does so well. What does this mean for Pfizer? I hope a lot, because I idiotically trusted that they would release COMPLETE information about the vaccines I went on to recommend (but now will not get or recommend) and it would be nice to hold them accountable. I'm talking to David about this at 1pm.

It's a parade like no other. Beijing displays thousands of troops — and three of the world's most controversial leaders — in a message directed straight at Washington, D.C. Plus, Venezuela's Maduro says the U.S. military buildup off his coast is nothing short of a push for regime change. He warned Tuesday morning that any conflict could trigger the biggest regional crisis in decades. Also, President Donald Trump now demands Pfizer and other drug companies prove their COVID-19 shots really work. These stories and more highlight your Unbiased Updates for Tuesday, Sept. 2, 2025.

KIMCHI ONE – heal your body from the inside out. Visit: https://mybrightcore.com/andweknow and get 25% off with code: AWK Or call (888) 317-9941) for up to 50% off! INTERVIEW: https://shorturl.at/sAe0b ——— AWK Shirts and gifts: https://shop.andweknow.com/ ———— Protect your investments with And We Know http://andweknow.com/gold Or call 720-605-3900, Tell them “LT” sent you. ------ AT sea with LT. 2026. Caribbean: https://www.inspirationtravel.com/event/lt-caribbean-cruise-2026 ————————— *Our AWK Website: https://www.andweknow.com/ ➜ AWK Shirts and gifts: https://shop.andweknow.com/ ------- Robert F Kennedy: "It's a trick". https://x.com/Humanspective/status/1962442350644568123 Elon Musk calls for Muslim Imam Abdullah Faaruuq (Boston, Massachusetts) to be deported after he declares white Americans should go back to Europe. https://x.com/RedWave_Press/status/1962670199112450450 Democrats on CNN are now passionately defending keeping children separated from their properly deported parents. https://x.com/Bubblebathgirl/status/1962630535873769741 Democrats in Michigan have been creating thousands of fake jobs and then laundering that money back to themselves https://x.com/WallStreetApes/status/1962499847594156257 RFK JR: “If you look at the studies that were done of the Pfizer vaccine … the people who got the vaccine had a 23% higher death rate from all causes” https://x.com/TheChiefNerd/status/1962600003534246209 ——  *DONATIONS SITE: https://bit.ly/2Lgdrh5 *Mail your gift to: And We Know 30650 Rancho California Rd STE D406-123 (or D406-126) Temecula, CA 92591 ➜ AWK Shirts and gifts: https://shop.andweknow.com/ ➜ Audio Bible https://www.biblegateway.com/audio/mclean/kjv/1John.3.16 Connect with us in the following ways: + DISCORD Fellows: https://discord.gg/kMt8R2FC4z

Send us a textTaylor & Travis get engaged…and the internet loses its mind. Then Charlie Kirk tells Taylor to “reject feminism, submit to your husband,” and implies marriage will “fix” her politics. If that's your gospel, it's not from Jesus. We break down the Taylor & Travis engagement and the Christian clickbait machine trying to hijack it. Come for the tea, stay for the theology.” We break it all down!Taylor Swift engagement, Travis Kelce, Charlie Kirk rant, Christian marriage, Ephesians 5, wives submit, mutual submission, faith and politics, culture war, conservative vs liberal, role model debate, name change marriage, marriage rates decline, Gen Z marriage, is marriage outdated, Pew poll marriage, clickbait outrage, Christian influencers, JD Vance reference, Pfizer discourse, Swifties, NFL celebrity couple, premarital counseling, healthy conflict, marriage experts, relationship podcast, Married AFTwo Awesome PeopleNew Episodes Every Monday and Thursday!Listen on: Apple Podcasts Spotify

3. When Politicians Panicked: The New Corona Virus, Expert Opinion, and a Tragic Lapse of Reason by John Tamney, argues that the severe economic contraction experienced in 2020 was primarily a consequence of politicians' panicked reactions and forced lockdowns, rather than the inherent lethality of the COVID-19 virus itself. Tamney highlights Governor Cuomo's March 20, 2020, decision to shut down New York, portraying the economy as a "valve" that could be arbitrarily opened and closed, which led to an immediate and severe contraction that persisted long after. The book contends that financial markets had already accounted for the virus's severity based on early signals from China, where US companies like Apple, GM, Nike, and Starbucks maintained strong performance, indicating the virus was not indiscriminately lethal. The real market panic, leading to a "very quick correction," occurred when politicians demonstrated their ability to "wreck an economy" through drastic actions like shutting down events such as South by Southwest in Texas. This response is contrasted with the 1968 Hong Kong flu pandemic, which caused 100,000 American deaths (equivalent to 250,000 today) but saw no significant market reaction or political lockdowns, primarily because technology at the time made such widespread closures impractical without risking "mass riots". Tamney criticizes the government's subsequent interventions, such as the CARES Act and the Paycheck Protection Program (PPP), for being akin to "central planning" imposed on top of political decrees. He argues these programs indiscriminately propped up entities like private schools, Harvard, and the Los Angeles Lakers, instead of allowing market forces to determine which businesses would adapt or fail. This "nationalization of investment" through government checks and loans was deemed anti-investment and merely delayed recovery by diverting capital from those most capable of investing to those most likely to consume, which does not drive economic growth. The author advocates for economic growth and individual freedom as the most effective responses to health threats. He points to examples like the voluntary disappearance of hand sanitizer and toilet paper before official shutdowns, and an individual living in a tent in Florida to protect his family despite no mandates, demonstrating that people don't need laws to avoid illness. Tamney suggests that a constitutional "right to contract" and return to work should protect individuals from such mandates. He concludes that the resilience shown by private enterprise, such as Pfizer developing a vaccine without "Operation Warp Speed" money, underscores that a healthy economy fostered by freedom is the best defense against disease. The core lesson, he asserts, is "never again take away people's freedom". 1919 DC.

2. When Politicians Panicked: The New Corona Virus, Expert Opinion, and a Tragic Lapse of Reason by John Tamney, argues that the severe economic contraction experienced in 2020 was primarily a consequence of politicians' panicked reactions and forced lockdowns, rather than the inherent lethality of the COVID-19 virus itself. Tamney highlights Governor Cuomo's March 20, 2020, decision to shut down New York, portraying the economy as a "valve" that could be arbitrarily opened and closed, which led to an immediate and severe contraction that persisted long after. The book contends that financial markets had already accounted for the virus's severity based on early signals from China, where US companies like Apple, GM, Nike, and Starbucks maintained strong performance, indicating the virus was not indiscriminately lethal. The real market panic, leading to a "very quick correction," occurred when politicians demonstrated their ability to "wreck an economy" through drastic actions like shutting down events such as South by Southwest in Texas. This response is contrasted with the 1968 Hong Kong flu pandemic, which caused 100,000 American deaths (equivalent to 250,000 today) but saw no significant market reaction or political lockdowns, primarily because technology at the time made such widespread closures impractical without risking "mass riots". Tamney criticizes the government's subsequent interventions, such as the CARES Act and the Paycheck Protection Program (PPP), for being akin to "central planning" imposed on top of political decrees. He argues these programs indiscriminately propped up entities like private schools, Harvard, and the Los Angeles Lakers, instead of allowing market forces to determine which businesses would adapt or fail. This "nationalization of investment" through government checks and loans was deemed anti-investment and merely delayed recovery by diverting capital from those most capable of investing to those most likely to consume, which does not drive economic growth. The author advocates for economic growth and individual freedom as the most effective responses to health threats. He points to examples like the voluntary disappearance of hand sanitizer and toilet paper before official shutdowns, and an individual living in a tent in Florida to protect his family despite no mandates, demonstrating that people don't need laws to avoid illness. Tamney suggests that a constitutional "right to contract" and return to work should protect individuals from such mandates. He concludes that the resilience shown by private enterprise, such as Pfizer developing a vaccine without "Operation Warp Speed" money, underscores that a healthy economy fostered by freedom is the best defense against disease. The core lesson, he asserts, is "never again take away people's freedom". 1918 SEATTLE

4. When Politicians Panicked: The New Corona Virus, Expert Opinion, and a Tragic Lapse of Reason by John Tamney, argues that the severe economic contraction experienced in 2020 was primarily a consequence of politicians' panicked reactions and forced lockdowns, rather than the inherent lethality of the COVID-19 virus itself. Tamney highlights Governor Cuomo's March 20, 2020, decision to shut down New York, portraying the economy as a "valve" that could be arbitrarily opened and closed, which led to an immediate and severe contraction that persisted long after. The book contends that financial markets had already accounted for the virus's severity based on early signals from China, where US companies like Apple, GM, Nike, and Starbucks maintained strong performance, indicating the virus was not indiscriminately lethal. The real market panic, leading to a "very quick correction," occurred when politicians demonstrated their ability to "wreck an economy" through drastic actions like shutting down events such as South by Southwest in Texas. This response is contrasted with the 1968 Hong Kong flu pandemic, which caused 100,000 American deaths (equivalent to 250,000 today) but saw no significant market reaction or political lockdowns, primarily because technology at the time made such widespread closures impractical without risking "mass riots". Tamney criticizes the government's subsequent interventions, such as the CARES Act and the Paycheck Protection Program (PPP), for being akin to "central planning" imposed on top of political decrees. He argues these programs indiscriminately propped up entities like private schools, Harvard, and the Los Angeles Lakers, instead of allowing market forces to determine which businesses would adapt or fail. This "nationalization of investment" through government checks and loans was deemed anti-investment and merely delayed recovery by diverting capital from those most capable of investing to those most likely to consume, which does not drive economic growth. The author advocates for economic growth and individual freedom as the most effective responses to health threats. He points to examples like the voluntary disappearance of hand sanitizer and toilet paper before official shutdowns, and an individual living in a tent in Florida to protect his family despite no mandates, demonstrating that people don't need laws to avoid illness. Tamney suggests that a constitutional "right to contract" and return to work should protect individuals from such mandates. He concludes that the resilience shown by private enterprise, such as Pfizer developing a vaccine without "Operation Warp Speed" money, underscores that a healthy economy fostered by freedom is the best defense against disease. The core lesson, he asserts, is "never again take away people's freedom". 1919 TEXAS

1.When Politicians Panicked: The New Corona Virus, Expert Opinion, and a Tragic Lapse of Reason by John Tamney, argues that the severe economic contraction experienced in 2020 was primarily a consequence of politicians' panicked reactions and forced lockdowns, rather than the inherent lethality of the COVID-19 virus itself. Tamney highlights Governor Cuomo's March 20, 2020, decision to shut down New York, portraying the economy as a "valve" that could be arbitrarily opened and closed, which led to an immediate and severe contraction that persisted long after. The book contends that financial markets had already accounted for the virus's severity based on early signals from China, where US companies like Apple, GM, Nike, and Starbucks maintained strong performance, indicating the virus was not indiscriminately lethal. The real market panic, leading to a "very quick correction," occurred when politicians demonstrated their ability to "wreck an economy" through drastic actions like shutting down events such as South by Southwest in Texas. This response is contrasted with the 1968 Hong Kong flu pandemic, which caused 100,000 American deaths (equivalent to 250,000 today) but saw no significant market reaction or political lockdowns, primarily because technology at the time made such widespread closures impractical without risking "mass riots". Tamney criticizes the government's subsequent interventions, such as the CARES Act and the Paycheck Protection Program (PPP), for being akin to "central planning" imposed on top of political decrees. He argues these programs indiscriminately propped up entities like private schools, Harvard, and the Los Angeles Lakers, instead of allowing market forces to determine which businesses would adapt or fail. This "nationalization of investment" through government checks and loans was deemed anti-investment and merely delayed recovery by diverting capital from those most capable of investing to those most likely to consume, which does not drive economic growth. The author advocates for economic growth and individual freedom as the most effective responses to health threats. He points to examples like the voluntary disappearance of hand sanitizer and toilet paper before official shutdowns, and an individual living in a tent in Florida to protect his family despite no mandates, demonstrating that people don't need laws to avoid illness. Tamney suggests that a constitutional "right to contract" and return to work should protect individuals from such mandates. He concludes that the resilience shown by private enterprise, such as Pfizer developing a vaccine without "Operation Warp Speed" money, underscores that a healthy economy fostered by freedom is the best defense against disease. The core lesson, he asserts, is "never again take away people's freedom". 1919 AUSTRALIA QUARENTINE.

On today's episode of Finding Freedom, John pulls back the curtain on several important stories and provides a personal update: He shares his own negative experience with Primo Brands and explains the unfolding class action lawsuit connected to the company. John gives an entrepreneurial update, highlighting the latest progress and challenges across his ventures. He covers the inspiring case of a 16-year-old in New York who won a major federal court victory securing medical exemptions from school vaccine mandates—an important moment in the fight for health freedom. Finally, John unpacks Donald Trump's call for Pfizer to release vaccine data, exploring what this demand means for Operation Warp Speed, accountability, and transparency in the pharmaceutical industry. This episode blends relevant personal updates, entrepreneurship, and critical health freedom issues—all from a liberty-minded perspective. We have a new show on Lions of Liberty! The Politicks Podcast! Be sure to subscribe to the standalone Politicks Podcast feed. This is the absolute best way to support the show! Listen and subscribe on Apple Podcasts and Spotify. And remember, they're all Blood Suckers! Subscribe to John's Finding Freedom Show solo feed to listen to “Pursuit of Freedom,” which is a new podcast series where John shares the highs and lows of his entrepreneurial journey. Listen and Subscribe on Apple Podcasts and Spotify. Follow the Lions of Liberty: Twitter Rumble YouTube Instagram Telegram Get access to all of our bonus audio content, livestreams, behind-the-scenes segments and more for as little as $5 per month by joining the Lions of Liberty Pride on Patreon OR support us on Locals! Check out our merchandise at the Lions of Liberty Store for all of our awesome t-shirts, mugs and hats! Learn more about your ad choices. Visit megaphone.fm/adchoices

On today's episode of Finding Freedom, John pulls back the curtain on several important stories and provides a personal update: He shares his own negative experience with Primo Brands and explains the unfolding class action lawsuit connected to the company. John gives an entrepreneurial update, highlighting the latest progress and challenges across his ventures. He covers the inspiring case of a 16-year-old in New York who won a major federal court victory securing medical exemptions from school vaccine mandates—an important moment in the fight for health freedom. Finally, John unpacks Donald Trump's call for Pfizer to release vaccine data, exploring what this demand means for Operation Warp Speed, accountability, and transparency in the pharmaceutical industry. This episode blends relevant personal updates, entrepreneurship, and critical health freedom issues—all from a liberty-minded perspective. We have a new show on Lions of Liberty! The Politicks Podcast! Be sure to subscribe to the standalone Politicks Podcast feed. This is the absolute best way to support the show! Listen and subscribe on Apple Podcasts and Spotify. And remember, they're all Blood Suckers! Subscribe to John's Finding Freedom Show solo feed to listen to “Pursuit of Freedom,” which is a new podcast series where John shares the highs and lows of his entrepreneurial journey. Listen and Subscribe on Apple Podcasts and Spotify. Follow the Lions of Liberty: Twitter Rumble YouTube Instagram Telegram Get access to all of our bonus audio content, livestreams, behind-the-scenes segments and more for as little as $5 per month by joining the Lions of Liberty Pride on Patreon OR support us on Locals! Check out our merchandise at the Lions of Liberty Store for all of our awesome t-shirts, mugs and hats! Learn more about your ad choices. Visit megaphone.fm/adchoices

In his weekly clinical update, Dr. Griffin with Vincent Racaniello are dismayed about the recent attack on public health the firing of the director of the CDC as well as resignation of 3 others members of the agency's leadership, the continued Legionnaire's outbreak in Harlem, suspension of Ixchiq the Chikungunya virus attenuated infectious vaccine, the first US case of New World screwworm before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, association Guillian-Barré syndrome with RSV vaccination, guidelines for using RSV vaccines, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines, the American College Obstetricians and Gynecologists recommendations for the COVID, RSV and influenza vaccines, FDA approval letters for Pfizer, moderna and Novagax COVID vaccines including label changes for use in those between 5 through 64 years, where to find PEMGARDA, long COVID treatment center, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode White House Says New C.D.C. Director Is Fired, but She Refuses to Leave (NY Times) CDC director refuses to leave after White House order (BBC) Legionnaires' Disease: In Harlem(NYC Health) New York City Health Department Provides Update on Community Cluster of Legionnaires' Disease in Central Harlem(NYC Health: Promoting and protecting the City's health) FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live) (FDA) Vimkunya (Bavarian Nordiac) U.S. and Panama for the control of the Screwworm pest (COPEG) Rare human case of flesh-eating parasite New World screwworm identified in US(CNN) USDA Announces Sweeping Plans to Protect the United States from New World Screwworm (USDA) HHS details New World screwworm response after human case(CIDRAP) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Measles vaccine recommendations from NYP (jpg) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score (JID) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) ENFLONSIA: novel drug approvals 2025 (FDA) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Evaluation of Guillain-Barré Syndrome (GBS) following Respiratory Syncytial Virus (RSV) Vaccination Among Adults 65 Years and Older (FDA) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Evidence to Recommendations Framework (EtR): RSV Vaccination in Adults Aged 50–59 years (CDC: National Center for Immunization and Respiratory Diseases) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Veering from CDC, ACOG recommends maternal vaccination against COVID-19 (CIDRAP) ACOG Releases Updated Maternal Immunization Guidance for COVID-19, Influenza, and RSV (American College of Obstericians and Gynecologists) COVID-19 Vaccination Considerations for Obstetric–Gynecologic Care (American College of Obstericians and Gynecologists) Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 (Pfizer)  COMIRNATY approval letter (FDA) Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 (FEEDS) SPIKEVAX approval letter (FDA) Novavax's Nuvaxovid 2025-2026 Formula COVID-19 Vaccine Approved in the U.S (Novavax) NUVAXOVID approval letter (FDA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Paxlovid (Pfizer) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1248 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.